Cue Biopharma raises ~$10M in dilutive public offering; cash runway through Q1 2027

Cue Biopharma, Inc.

Gross proceeds ~$10M from 35.7M shares/pre-funded warrants and 17.9M warrants at $0.28 combined offering price.
Net proceeds ~$8.9M (~$10.3M if underwriters exercise full option), after underwriting discounts and expenses.
Cash runway extended into Q1 2027 based on net proceeds, existing cash, and expected $10M from ImmunoScape collaboration.
Underwriters have 30-day option to purchase up to 5,357,140 additional shares and 2,678,570 warrants.

item 1.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.